BCL2 and neoplasm: It has been shown that the upregulated hub MMRG genes BCL2, MAVS, FKBP8, NBR1, and SLC25A6 and their products can participate in regulating drug resistance of tumour cells and the antitumour immune response and may be associated with the activation of inflammatory signalling pathways [76,77,78,79,80,81,82,83,84,85].